Local pharmaceutical company wins FDA approval for study of Alzheimer's and dementia drug

Alzamend Neuro can move forward with Phase 1 clinical study of AL001, a treatment for Alzheimer’s disease and dementia.

  • By Business Observer Staff
  • | 3:40 p.m. July 28, 2021
FILE: Alzamend Neuron can move forward with Phase 1 clinical study of AL001, a treatment for Alzheimer’s disease and dementia.
FILE: Alzamend Neuron can move forward with Phase 1 clinical study of AL001, a treatment for Alzheimer’s disease and dementia.
  • Tampa Bay-Lakeland
  • Share

TAMPA —Alzamend Neuro has received permission from the U.S. Food and Drug Administration to move forward with a Phase 1 clinical study of AL001, a treatment for patients with Alzheimer’s disease and dementia.

 

Continue reading your article
with a Business Observer subscription.
What's included:
  • ✓ Unlimited digital access to BusinessObserverFL.com
  • ✓ E-Newspaper app, digital replica of print edition
  • ✓ Mailed print newspaper every Friday (optional)
  • ✓ Newsletter of daily business news
Subscribe

Already subscribed? Sign in.

Latest News

  • February 22, 2026
Report: Florida ranks No. 2 in statewide foreclosure pressure
  • February 21, 2026
Retired attorney, family donate $10M to Naples hospital
  • February 20, 2026
Fort Myers portfolio sells for $30 million
  • February 20, 2026
Port Charlotte industrial portfolio gets nearly $4 million refinancing

Sponsored Content